Compare HOUR & RLYB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HOUR | RLYB |
|---|---|---|
| Founded | 2015 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 77.4M | 92.3M |
| IPO Year | 2021 | 2021 |
| Metric | HOUR | RLYB |
|---|---|---|
| Price | $1.82 | $15.95 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 63.6K | 37.4K |
| Earning Date | 05-13-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 150.00 | N/A |
| EPS | ★ 0.02 | N/A |
| Revenue | ★ $142,440,236.00 | $858,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $92.00 | ★ N/A |
| Revenue Growth | 3.03 | ★ 43.00 |
| 52 Week Low | $1.24 | $0.39 |
| 52 Week High | $6.84 | $17.57 |
| Indicator | HOUR | RLYB |
|---|---|---|
| Relative Strength Index (RSI) | 45.56 | 57.94 |
| Support Level | $1.75 | $15.59 |
| Resistance Level | $2.12 | $17.57 |
| Average True Range (ATR) | 0.15 | 0.43 |
| MACD | -0.00 | -0.15 |
| Stochastic Oscillator | 19.40 | 24.73 |
Hour Loop Inc is a technology-enabled consumer products company that uses machine learning and data analytics to design, develop, market, and sell products. Hour Loop predominantly operates through online retail channels such as Amazon, Walmart, and Hourloop.com. The company, as an Internet marketplace seller, sells products in multiple categories, including home/garden decor, toys, kitchenware, apparel, and electronics. It has only one segment, which is online retail (e-commerce).
Rallybio Corp is a clinical-stage biotechnology company comprised of experienced biopharma industry leaders with extensive research, development, and rare disease expertise with a mission to develop and commercialize life-transforming therapies for patients with severe and rare diseases. The company's program, RLYB116, is a differentiated complement component 5 (C5) inhibitor with the potential to treat diseases of complement dysregulation. The Company manages its operations as a single segment for the purposes of allocating resources, assessing performance, and making operating decisions. Rallybio's pipeline also includes RLYB332, a preclinical long-acting matriptase-2 antibody for the treatment of diseases of iron overload.